Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free SurvivalAndrea Lo, Ingrid Spadinger, William Morris et al.|International Journal of Radiation Oncology*Biology*Physics|2013Cited by 58
Population-Based Study of Stereotactic Radiosurgery or Fractionated Stereotactic Radiation Therapy for Vestibular Schwannoma: Long-Term Outcomes and ToxicitiesAndrea Lo, Alan Nichol, Boris Valev et al.|International Journal of Radiation Oncology*Biology*Physics|2017Cited by 26
Patterns of Recurrence After Low-Dose-Rate Prostate Brachytherapy: A Population-Based Study of 2223 Consecutive Low- and Intermediate-Risk PatientsAndrea Lo, Scott Tyldesley, William Morris et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 19
Canadian patterns of practice for intracranial germ cell tumors in adolescents and young adultsAndrea Lo, Karen Goddard, Normand Laperrière et al.|Journal of Neuro-Oncology|2019Cited by 11
Prognostic Utility of the Prostate Specific Antigen (PSA) Value 4-5 Years After 125I BrachytherapyAndrea Lo, Ingrid Spadinger, William Morris et al.|International Journal of Radiation Oncology*Biology*Physics|2013Cited by 0